J&J’s Spravato Gets EU Okay For Drug-Resistant Depression
Nasal Spray Completes Approval Process Unscathed
Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.
You may also be interested in...
The EMA has received written interventions from third parties relating to its CHMP opinion that the controversial antidepressant should receive EU approval.
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.